Tritolyl phosphates have caused many cases of poisoning in humans involving damage to. the nervous system which is characterized clinically by ataxia and paralysis of the limbs (Smith, Elvove, Valaer, Frazier & Malleroy, 1930; Henschler, 1958) ; also, in the hen a similar type of poisoning is produced and this species is therefore accepted as a suitable experimental animal for studying this type of neurotoxicity . Other organophosphorus compounds, e.g. di-isopropyl phosphorofluoridate and NN'-di-isopropyl phosphorodiamidic fluoride (Barnes & Denz, 1953 ) and a further series of phosphonofluoridates (Davies, Holland & Rumens, 1960) , produce a similar effect in chickens. Although trio-tolyl phosphate is effective many other tri(alkylphenyl) phosphates are ineffective (Hine et al. 1956 ; Henschler, 1958 Henschler, , 1959 , and in a more recent study out of 23 tri(alkylphenyl) phosphates only nine produced ataxia in chickens (Bondy, Field, Worden & Hughes, 1960;  Aldridge & Barnes, 1961) .
From all of these studies no overall correlation between chemical structure and neurotoxicity has been established. Although many of these compounds produce inhibition of pseudo-cholinesterase of the chicken, this cannot be correlated with neurotoxicity (Davison, 1953; Aldridge & Barnes, 1961) . Nevertheless, it is true that all of the compounds capable of inducing neurotoxicity have the property of inhibiting enzymes possessing carboxylic esterase activity in vitro or are converted in vivo into compounds that have this property (Aldridge, 1954a;  Aldridge & Barnes, 1961; . Therefore the possibility exists of a correlation between neurotoxicity and inhibition of esterases other than cholinesterases. This was the reason for the present study of esterases of the chicken central nervous system.
One of the problems in the study of esterases is that their physiological substrates are not usually known and the selection of substrates is largely guesswork. However, two facts suggested to us that, in this instance, a more logical approach might be made. Tri-o-tolyl phosphate is metabolized in vivo (Aldridge, 1954a) and a cyclic * Present address: Department of Pharmacology and Toxicology, Royal Veterinary and Agricultural College, Copenhagen, Denmark. phosphate (cf. Fig. 1 ) has been isolated; the neurotoxicity and anti-esterase activity of both the synthetic compound and the isolated material are very high and are identical Baron, Bennett & Casida, 1962; Eto, Casida & Eto, 1962) . Since inhibition of esterases by organophosphorus compounds and hydrolysis of substrates are in principle identical processes (see review by Aldridge, 1956) , carboxylic esters analogous to the metabolite from tri-o-tolyl phosphate have been synthesized and used as substrates for the present studies. A preliminary account of this work has been presented (Poulsen & Aldridge, 1963 (Casida, Baron, Eto & Engel, 1963) The esters were synthesized by a method described by Huggins & Lapides (1947) as modified by Aldridge (1953 b Homogenizing and storage procedure. The chickens were killed by breaking their necks. The brain and spinal cord were dissected out. The brain stem was cut between the pons and medulla; the medulla and the cranial and haemorrhagic part of the spinal cord were discarded. The brain or spinal cord was immediately placed in ice-cold buffer [NaCl (150 mM) and NaHCO3 (35-8 mM) ], blotted free from blood and buffer, weighed and homogenized in buffer in a Nelco homogenizer (8000-10000 rev./min. for 2 min.). The homogenates were kept in ice until use later the same day. Storage for longer periods was at -5°. The esterase activity of brain was stable under these conditions for at least 7 days and of spinal cord for 4 days with not more than 10 % loss. After storage of tissues intact at -180 for long periods they showed no difference in activity from fresh tissue. Other tissue homogenates were prepared in the same way.
Manometric determination of esterase activity. Determinations were carried out in Warburg apparatus at 370 in a medium containing NaHCO2 (35.8 mM), NaCl (150 mM) and gelatin (05%). The tissue homogenates were tipped in from the side arm of the Warburg flask after gassing and equilibration with C02+ N2 (5:95). Soluble substrates (acetylcholine chloride and n-butyrylcholine perchlorate) were dissolved in, and liquid substrates (phenyl butyrate, tributyrin and phenyl 3-phenylpropionate) were emulsified with, the buffer-gelatin mixture in the main compartment of the Warburg flask. The other solid less-soluble substrates were, in the preliminary experiments (Table 1) , dissolved in dimethylformamide and added to the buffer in the main compartment. When it was found that the concentration of dimethylformamide used (10%) decreased the activity by approx. 6% its use was stopped and the substrates were homogenized in the buffer-gelatin mixture with an all-glass homogenizer. The overall concentration of substrates was 10 mM except for acetylcholine chloride (14 mM), n-butyrylcholine perchlorate (30 mM), tributyrin (50 mM), phenylbutyrate (91 mM), benzyl benzoate (50 mM) and phenyl-3-phenylpropionate (20 mM). During the manometric determination, readings were taken at intervals of 5 min. for the first 30 min. The output was in most cases linear with respect to time; for the substrate phenyl phenylacetate a linear relationship was found up to 6 1l. of C02/min. In all cases the rate of CO2 evolution was linear with respect to enzyme concentration. Enzyme activities were obtained by calculating the best straight line by the method of Aldridge, Berry & Davies (1949) and expressed as ul. of C02/g. wet.wt. of tissue/min.
Inhibition experiments. Solutions of water-soluble inhibitors were freshly prepared in the buffer used for homogenizing. The more insoluble organophosphorus compounds (tri-o-tolyl phosphate and tri-p-tolyl phosphate) were dissolved in dimethylformamide and the same amount of dimethylformamide was added to the control flasks. In all experiments in vitro the time of inhibition was 30 min. and the temperature 37°. The stated concentration of inhibitor was the concentration during incubation and before mixing with substrate, except in experiments with neostigmine where it was the concentration after mixing with the substrate. In the preliminary experiments the enzyme and the inhibitor were mixed and incubated in the side arm of the flask. For most experiments and always when two substrates were compared the following technique was used. A sample (1-5 ml.) of the suitably diluted tissue homogenate was placed in glass-stoppered tubes in an ice bath. To each tube was added a suitable volume of the inhibitor solution in buffer or in dimethylformamide (at 100 times the final concentration required) and as quickly as possible a suitable volume (up to 0-8 ml.) of the mixture in the tubes was placed in the side arm of the flask, and used for the determination of the residual enzymic activity. The time of inhibition (30 min.) was the time of incubation from the placing of the flask in the Warburg bath to mixing with the substrate by tipping in the content of the side arm. Gassing, equilibration etc., took place during the incubation.
Fractionation procedure. After decapitation of the chicken the brain was removed, rinsed in ice-cold 0-3M-sucrose, rough dried and weighed. One brain was homogenized in 15 ml. of ice-cold 03 M-sucrose by using a smooth glass tube and Perspex pestle with an all-round clearance of 0-005 in. (Aldridge, Emery & Street, 1960) . The homogenate was diluted to 25 ml. with sucrose and was divided by centrifuging at 145 0OOg for 60 min. at 00 into two fractions, a particulate and a supernatant. The precipitate was re-homogenized in 15 ml. of 0-3M-sucrose and centrifuged as before, the supernatant discarded and the precipitate kept.
The protein content of chicken brain, determined by a modification (Aldridge, 1957) of the biuret method of Robinson & Hogden (1940) , was found in two experiments to be 94 and 89-4 mg. of protein (as albumin)/g. wet wt. of brain; 71-9% and 25-0% was recovered in the particulate and supernatant fractions respectively.
RESULTS
Selection of substrates. In Table 1 the rates of hydrolysis of phenyl phenylacetate and other esters with a similar structure are compared with the rates of hydrolysis of acetylcholine, n-butyrylcholine, tributyrin and phenyl butyrate. Benzyl benzoate, phenyl benzoate and the more-soluble p-nitrophenyl benzoate were hydrolysed slowly. The activity against the tolyl and ethylphenyl esters of phenylacetic acid was about one-third of the rate of hydrolysis of phenyl phenylacetate, whereas p-nitrophenyl phenylacetate was hydrolysed at a higher rate than was phenyl phenylacetate. The relatively high rate of spontaneous hydrolysis and a considerable variation in results from the same homogenate made this p-nitrophenyl ester unsuitable for further experiments. Phenyl 3-phenylpropionate was hydrolysed five times as fast as phenyl phenylacetate and at a rate as high as that of acetylcholine, whereas phenyl 4-phenylbutyrate was hydrolysed at a rate less than half that of phenyl phenylacetate.
Since the identity of the compounds is beyond reasonable doubt (see the Methods and Materials section) the differences in the rates of hydrolysis of the such closely related members of an homologous series are noteworthy. It was therefore decided to use phenyl phenylacetate and phenyl 3-phenylpropionate for further experiments.
Hydrolysis of phenyl phenylacetate and phenyl 3-phenylpropionate by cholinesterases. To investigate whether phenyl phenylacetate and phenyl 3.phenylpropionate were hydrolysed by cholinesterases, experiments with the cholinesterase inhibitor neostigmine were performed (Table 2) . With both spinal cord and brain preparation the hydrolysis of the two choline esters, acetyl-and n-butyryl-choline, was nearly completely inhibited by concentrations of neostigmine 10-100-fold less than those which had very little influence on the hydrolysis of phenyl phenylacetate and phenyl 3-phenylpropionate. These two substrates are therefore apparently not hydrolysed at appreciable rates by cholinesterases in brain and spinal cord.
Inhibition of the hydrolysis of phenyl phenylacetate and phenyl 3-phenylpropionate by organophosphorus compounds. Organophosphorus compounds are known to be inhibitors of many enzymes with carboxylic esterase activity (Aldridge, 1956) and have been used to discriminate between the different enzymes with esterase activity which are present in tissue homogenates (Aldridge, 1953b (Aldridge, , 1954b Myers, Schotte, Boer & Borsje-Bakker, 1955; Myers, 1956 ). The hydrolysis of phenyl (Table 3) , the last-named being the most active (cf. Fig. 1 ). With DFP and mipafox e incubated for 30 min. at a difference in the sensitivity of the hydrolysis of ions of inhibitor before the the two substrates was found with both brain and concentrations of inhibitors spinal cord (see below). In other experiments this i hibition was determined was shown to be true also for sciatic nerve (Table 4) (Fig. 2) . A similar but less pronounced discrimination was found in brain in experiments with 100-fold lower I with inhibitor for 30 min. concentrations of DFP (Fig. 3) . uperature will be the same illustrate this point. As the concentration of ins used. That the degree of bibitor is increased the inhibition increases but not ;ame in this case shows that to the same degree with each substrate. The phenyl te is present, and they must 3-phenylpropionate :phenyl phenylacetate ratio 6te specificity. The results in alters with increasing inhibition and increases :een regraphed in Fig. 4 to rapidly from 4-5 to approx. 10 and then stays constant. Though this ratio stays constant with increasing inhibitor concentration the inhibition is increasing; the enzyme with a ratio of 10 therefore fulfils the criteria discussed above for a single enzyme hydrolysing both substrates. Our experiments with DFP and mipafox give evidence for the presence in brain homogenates of three different enzymes hydrolysing phenyl 3-phenylpropionate and phenyl phenylacetate: (a) a variable amount of an enzyme which is sensitive to 0.1,km-mipafox; (b) an enzyme which is inhibited by approx. 3/uM-DFP and 0-3 mM-mipafox and with a phenyl 3-phenylpropionate: phenyl phenylacetate ratio of less than 5 ( Experiment8 with tri-o-tolyl pho8phate. Pure pafox of the hydrolysis of phenyl tri-o-tolyl phosphate had no inhibitory effect in henyl 3-phenylpropionate (0) in vitro on human-serum cholinesterase and rat-serum e inhibition was estimated by 'tributyrinase' (Aldridge, 1954a After oral administration to chickens of 0 5-2-0 ml. of tri-o-tolyl phosphate/kg. body wt. the esterase activity against phenyl phenylacetate both in brain and spinal cord was inhibited 50 % or more, whereas the hydrolysis of phenyl 3-phenylpropionate was less inhibited (Table 5) . As a result the phenyl 3-phenylpropionate: phenyl phenylacetate ratio was higher in treated chickens (approx. 7-8) than in the untreated ones (approx. 5). There was no apparent difference between the doses 0-5 and 2-0 ml./kg. even if the 2-0 ml./kg. was given as 0 5 ml. for 4 consecutive days. These results show that tri-o-tolyl phosphate in the chickens is metabolized to an inhibitor of the enzymes hydrolysing phenyl phenylacetate and phenyl 3-phenylpropionate; since there are several possible metabolites (Eto et al. 1962) it is not possible to say anything about the structure of the inhibiting metabolite(s). These results provide further indications of the presence of more than one enzyme hydrolysing phenyl 3-phenylpropionate and phenyl phenylacetate.
Attempts to fractionate the enzymes. Brain homogenates were prepared in 0-3M-sucrose and these were separated by centrifuging into particulate and supernatant fractions. The phenyl 3-phenylpropionate:phenyl phenylacetate hydrolysis ratio in the particulate fraction was a little lower (3 5) than in the whole homogenate (4-5). In the supernatant a higher ratio (8-9) was found. The activity recovered in the supernatant was only 10-20 % of the total activity. The difference in ratios of activities shows the presence of more than one enzyme hydrolysing phenyl 3-phenylpropionate and phenyl phenylacetate. However, although the recovery of protein in the two fractions was 97 %, the recovery of activity against phenyl 3-phenylpropionate and phenyl phenylacetate was only 77 0 and 85-2 % respectively. We have not been able to improve on this recovery and therefore no conclusions about distribution may be made.
Hydrolysis of phenyl phenylacetate and phenyl 3-phenylpropionate by different tissues. The activity in the blood is very low, and that in pancreas, intestinal mucosa, kidney and liver high, compared with that in the central nervous system (Table 6 ). The phenyl 3-phenylpropionate: phenyl phenylacetate hydrolysis ratios are, in all tissues except pancreas, different from those obtained for the central nervous system. Experiments with tri-ptolyl phosphate, which is a very active inhibitor of the hydrolysis of phenyl butyrate by the chicken liver (Aldridge & Barnes, 1961) , showed ( Table 7) that esterases hydrolysing phenyl 3-phenylpropionate and phenyl phenylacetate in the central nervous system (and pancreas) are resistant to that inhibitor in concentrations 10-100 times those giving a considerable inhibition with other tissues. Thus the enzymes hydrolysing phenyl 3-phenylpropionate and phenyl phenylacetate in the central nervous system are apparently different from those of most other tissues.
DISCUSSION
Compared with those on some tissues, and other than some histochemical work, there have been relatively few publications on the esterases, excluding cholinesterases, of the central nervous system (Cohn, Kaplan & Janota, 1941; Mendel & Myers, 1953; Mendel, Myers, Uyldert, Ruys & De Bruyn, 1953; Aldridge, 1954b; Myers, 1956; Myers, (1) 2429 (1) 98 (1) 112 (1) 471 (1) 1103 (1) 227 (1) 815 (1) Phenyl (Table 1) .
It is now well established that the inhibition of esterases by organophosphorus compounds is in principle the same type of reaction as that involved in the hydrolysis of substrates (Aldridge, 1956) . Thus the same structural features that, in a substrate, enable rapid enzymic hydrolysis to take place will, in an organophosphorus compound, increase the inhibitory activity (Aldridge, 1953a; Heath, 1961; Becker, Fukuto, Boone, Canhan & Boger, 1963) . In the present paper this concept has been used inversely and the structures of possible substrates have been derived from organophosphorus compounds. This logical approach has been successful in that the two esters chosen are hydrolysed rapidly by brain and, among the inhibitors tested, are most sensitive to inhibition by the organophosphorus analogue phenyl saligenin phosphate.
SUMMARY
1. The hydrolysis of various esters by chicken brain and spinal cord has been studied.
2. The hydrolyses of phenyl phenylacetate and phenyl 3-phenylpropionate have been studied in detail and the effects of various inhibitors determined.
3. By using the organophosphorus compounds di-isopropyl phosphorofluoridate and NN'-di-iso-propyl phosphorodiamidic fluoride it has been established that phenyl phenylacetate and phenyl 3-phenylpropionate are hydrolysed by two or more esterases.
4. These esterases are present in brain, spinal cord and sciatic nerve.
